bioAffinity Q3 26 Results; Lung Revenue Up 79%
bioAffinity reported a 79% increase in testing revenue for Q3 2026, driven by double unit sales of CyPath Lung in the first nine months. The company expanded government distribution and clinical utilization.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed